This article was originally published in The Tan Sheet
Executive SummaryEffective television advertising drove a 51% increase in spoon-delivered multi-symptom cold and flu relief SKU products sales during the 2007 first quarter, the Phoenix-based Zicam manufacturer reports in a May 30 regulatory filing. The firm reports its Zicam Nasal Moisturizer product was dropped from the allergy and sinus line after it failed to gain widespread distribution in 2006, however the company plans to ramp up offerings in that category with Zicam Sinus Rapid Melt with vapor action set to launch in the second half of 2007. Quarterly net sales hit $19 mil., a 7.7% increase from a year ago, the firm says. Other results include: cold remedy product sales were up 0.4% to $11.5 mil., allergy, sinus and nasal comfort sales climbed 16.1% to $4.6 mil., cough product sales increased 8% to $1.1 mil. and multi-symptom cold and flu relief sales rose 50.9% to $1.8 mil...
You may also be interested in...
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.
The US agency is engaged with an ethylene oxide (EtO) sterilizer in Illinois that has temporarily closed to determine if there are any potential risks to the medical device supply chain. While the plant shut down about a month ago, regulators have only recently been made aware of the decision, which resulted from a law passed last year by the state legislature.
Pfizer's biosimilar franchise is well on its way to becoming a blockbuster business three years after the company launched its first US biosimilar.